{"gene":"GPR143","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2008,"finding":"L-DOPA is an endogenous ligand for OA1/GPR143. Radiolabeled ligand binding confirmed a single, saturable binding site for L-DOPA. OA1 activation by L-DOPA triggers intracellular calcium influx and beta-arrestin recruitment. Dopamine competed with L-DOPA for the OA1 binding site, suggesting it acts as an antagonist. OA1 stimulation in RPE with L-DOPA results in increased PEDF secretion, forming an autocrine loop with tyrosinase.","method":"Radiolabeled ligand binding assay, intracellular calcium influx measurement, beta-arrestin recruitment assay, PEDF secretion assay, tyrosinase inhibition experiments in RPE cells and transfected cell lines","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal in vitro assays (radioligand binding, second messenger, beta-arrestin) in one rigorous study establishing ligand identity and receptor activation mechanism","pmids":["18828673"],"is_preprint":false},{"year":2006,"finding":"OA1 expressed in COS7 cells activates heterotrimeric G proteins spontaneously. OA1 mutants with missense mutation or deletion in the third cytosolic loop lack this ability. OA1 is phosphorylated, colocalizes and coprecipitates with arrestins, and arrestins downregulate OA1 signaling by reducing its expression levels.","method":"Heterologous expression in COS7 cells, G protein activation assay, co-immunoprecipitation with arrestins, colocalization immunofluorescence, phosphorylation assay","journal":"Pigment cell research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (G protein activation, co-IP, phosphorylation, mutagenesis) in a single study establishing GPCR functional properties","pmids":["16524428"],"is_preprint":false},{"year":2006,"finding":"OA1 intracellular targeting to lysosomes and melanosomes requires two separate sorting signals: an unconventional dileucine motif in the third cytosolic loop and a novel tryptophan-glutamic acid (WE) doublet in the C-terminal tail. Both motifs must be simultaneously mutated to redirect OA1 to the plasma membrane, indicating they independently drive intracellular targeting.","method":"Chimeric protein constructs (OA1 cytosolic domains fused to LAMP1 lumenal/TM domains), missense and deletion mutagenesis, subcellular localization by immunofluorescence in melanocytic and non-melanocytic cells","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution with chimeric proteins plus mutagenesis plus functional localization readout, single lab but multiple orthogonal approaches","pmids":["16621890"],"is_preprint":false},{"year":2007,"finding":"OA1, properly localized to intracellular lysosomal organelles, spans the membrane seven times with its C-terminus directed to the cytoplasm, confirming its topology as an intracellular 7-transmembrane GPCR.","method":"HA-tag insertion into predicted cytosolic/luminal regions, selective plasma membrane permeabilization leaving endolysosomal membranes intact, immunofluorescence accessibility assay in COS-1 cells","journal":"Experimental eye research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct membrane topology mapping by selective permeabilization and HA-tag accessibility, rigorous controls with LAMP1 reporter","pmids":["17920058"],"is_preprint":false},{"year":2009,"finding":"OA1 interacts biochemically with the premelanosomal protein MART-1. MART-1 loss by siRNA reduces OA1 stability and causes similar defects in premelanosome biogenesis and composition, indicating MART-1 acts as an escort protein for OA1. OA1 loss of function leads to decreased pigmentation and formation of enlarged aberrant premelanosomes with disorganized fibrillar structures displaying mislocalized mature melanosome and lysosome membrane proteins.","method":"siRNA inactivation of OA1 and MART-1 in human pigmented melanocytic cells, co-immunoprecipitation, electron microscopy of melanosome ultrastructure, immunofluorescence of melanosomal protein localization","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal biochemical interaction plus functional KD phenotypes with multiple orthogonal readouts (co-IP, EM, IF) in a single study","pmids":["19717472"],"is_preprint":false},{"year":2008,"finding":"OA1 coimmunoprecipitates with the Gαi subunit of heterotrimeric G proteins from human melanocyte extracts. Gαi3-deficient mice phenocopy Oa1-deficient mice with reduced melanosome density, enlarged melanosomes, and reduced ipsilateral retinofugal projections, placing Gαi3 in the same pathway as OA1.","method":"Co-immunoprecipitation from human melanocyte extracts; genetic epistasis using Gαi3-/- and Oa1-/- mouse models; light and electron microscopy of RPE melanosomes; retrograde labeling of optic pathway","journal":"Investigative ophthalmology & visual science","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP plus genetic epistasis with knockout mice and multiple phenotypic readouts, independently supported by subsequent studies","pmids":["18378571"],"is_preprint":false},{"year":2011,"finding":"Among Gαi subfamily members, Gαi3 specifically binds to Oa1. GST pull-down and immunoprecipitation assays demonstrate that only Gαi3 (not Gαi1 or Gαi2) interacts with Oa1. Gαi3 expression is barely detectable in Oa1-/- RPE, indicating Oa1 is required for Gαi3 stability in this tissue.","method":"GST pull-down, co-immunoprecipitation, Western blotting in Gαi1-/-, Gαi2-/-, Gαi3-/- and double knockout mice, RPE morphometry by electron microscopy","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct biochemical binding assays (GST pull-down + co-IP) with multiple genetic controls establishing specificity of the Oa1–Gαi3 interaction","pmids":["21931697"],"is_preprint":false},{"year":2013,"finding":"A constitutively active Gαi3 (Q204L) expressed in the RPE of Oa1-/- mice rescues the normal melanosomal phenotype, restoring higher melanosome density and normal small melanosome size, demonstrating that Gαi3 is the downstream effector of Oa1 in melanosome biogenesis.","method":"Lentiviral transgenesis of constitutively active Gαi3(Q204L) in Oa1-/- RPE; electron microscopy morphometry; PCR, Southern, Western blot, confocal microscopy for transgene confirmation","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic rescue experiment with constitutively active downstream effector, rigorous morphometric quantification by EM","pmids":["24098784"],"is_preprint":false},{"year":2011,"finding":"OA1 is ubiquitinated, and its intracellular sorting and degradation require functional ESCRT-0, -I, and -III components. OA1 ubiquitination is specifically required for its targeting to intraluminal vesicles of multivesicular endosomes, regulating the balance between degradation and delivery to melanosomes.","method":"Biochemical ubiquitination assays, overexpression and siRNA depletion of ESCRT subunits, morphological analysis by immunofluorescence and electron microscopy","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — biochemical (ubiquitination assay) plus functional (ESCRT depletion/overexpression) plus morphological readouts, multiple orthogonal methods in one study","pmids":["21730137"],"is_preprint":false},{"year":2023,"finding":"GPR143 controls ESCRT-dependent exosome biogenesis by interacting with HRS (ESCRT-0 subunit) and promoting HRS association with cargo proteins such as EGFR, enabling selective protein sorting into intraluminal vesicles in multivesicular bodies. GPR143-driven exosome secretion carries integrin signaling proteins and promotes cancer cell motility/invasion through the integrin/FAK/Src pathway.","method":"Co-immunoprecipitation of GPR143 with HRS and EGFR; quantitative proteomics and RNA profiling of exosomes; gain- and loss-of-function in mouse cancer models; cell motility/invasion assays","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, quantitative proteomics, in vivo gain/loss-of-function, multiple orthogonal methods establishing a new mechanistic role","pmids":["36800996"],"is_preprint":false},{"year":2013,"finding":"OA1 expression (but not signaling-deficient OA1 mutants) increases MVB numbers and inhibits lysosomal delivery of PMEL-containing MVBs without affecting EGFR-containing MVB degradation, indicating OA1 activity selectively delays PMEL-MVB fusion with lysosomes to allow commitment to melanosome biogenesis.","method":"OA1 wild-type and inactivating mutant expression in HeLa cells expressing PMEL; quantification of MVB numbers by electron microscopy; EGFR degradation assay; PMEL delivery to lysosome assay","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — functional mutagenesis with EM morphometry and biochemical cargo-tracking assays, multiple orthogonal methods distinguishing OA1-specific from non-specific MVB effects","pmids":["24006264"],"is_preprint":false},{"year":2000,"finding":"Missense mutations in OA1 cause two distinct biochemical defects: ~60% cause ER retention with defective glycosylation (protein misfolding), while ~40% traffic normally but cluster in the second and third cytosolic loops critical for G protein coupling and effector activation.","method":"Expression of 19 missense mutants in COS-7 cells, analysis of subcellular distribution by immunofluorescence, glycosylation analysis by biochemical methods","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic analysis of 19 mutants with two orthogonal readouts (localization + glycosylation) establishing structure-function relationships","pmids":["11115845"],"is_preprint":false},{"year":2000,"finding":"Oa1 knockout mice display giant melanosomes (macromelanosomes) in RPE formed by abnormal growth of single melanosomes rather than fusion, and show reduced size of the uncrossed retinofugal pathway (optic fiber misrouting), establishing Oa1 as required for melanosome size regulation and normal optic pathway development.","method":"Gene targeting knockout mouse; electron microscopy of RPE; retrograde labeling of retinofugal pathway; ophthalmologic examination","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with EM ultrastructural analysis and neuroanatomical pathway tracing, replicating the human disease phenotype","pmids":["11092754"],"is_preprint":false},{"year":2005,"finding":"Oa1 controls melanosome biogenesis at two stages: at early maturation stages it controls the abundance (number) of melanosomes in RPE cells, and at later stages (stage IV) it controls organelle size. This was established using double-knockout mice combining Oa1 null with either Tyr or Matp mutations that block melanosome maturation at stages II and III respectively.","method":"Genetic epistasis with double-knockout mice (Oa1-/-;Tyr(c-2J) and Oa1-/-;Matp(uw)); electron microscopy morphometry; immunohistochemistry of tyrosinase activity","journal":"Investigative ophthalmology & visual science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — double-knockout genetic epistasis with EM morphometry, cleanly placing OA1 function at two distinct steps of melanosome maturation","pmids":["16303920"],"is_preprint":false},{"year":2014,"finding":"OA1 loss of function reduces basal and α-MSH/cAMP-induced MITF expression, which in turn reduces PMEL expression without affecting tyrosinase or melanin levels. OA1 re-expression rescues melanosome biogenesis and activates MITF expression, establishing an OA1→MITF→PMEL transcriptional cascade for melanosome quality control.","method":"OA1 loss-of-function and rescue in melanocytes; qRT-PCR and Western blot for MITF and PMEL; α-MSH stimulation assays; melanosome morphometry","journal":"Pigment cell & melanoma research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional rescue with molecular pathway readouts, single lab, two orthogonal methods","pmids":["24650003"],"is_preprint":false},{"year":2012,"finding":"Melanoregulin (MREG) interacts with both BLOC-2 complex members and Oa1, linking the BLOC pathway to Oa1 in melanosome size regulation. Transgenic overexpression of melanoregulin in Oa1-knockout mice corrects macromelanosome size in RPE, while MREG loss enlarges micromelanosomes in BLOC-2 mutants.","method":"Co-immunoprecipitation of MREG with Oa1 and BLOC-2 members; Oa1 knockout mouse crossed with MREG transgenic mouse; electron microscopy of RPE melanosomes","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus genetic rescue experiment, single lab","pmids":["22984402"],"is_preprint":false},{"year":2014,"finding":"OA1/GPR143 functions as a receptor for L-DOPA in the nucleus tractus solitarii (NTS) in vivo. OA1 shRNA knockdown in the NTS blocked depressor and bradycardic responses to microinjected L-DOPA but not to glutamate. A competitive OA1 antagonist (DOPA cyclohexyl ester) suppressed phenylephrine-induced bradycardic responses.","method":"Immunohistochemistry of OA1 in NTS; adenoviral shRNA knockdown of OA1 in NTS; blood pressure and heart rate measurements after DOPA microinjection in anesthetized rats; pharmacological antagonism","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function (shRNA) with pharmacological antagonism, two orthogonal approaches establishing receptor function in a defined CNS nucleus","pmids":["24117106"],"is_preprint":false},{"year":2015,"finding":"Morpholino-mediated knockdown of OA1 in zebrafish RPE induces a major reduction in melanosome number, recapitulating the mammalian disease. Melanosome number (controlled by OA1) and melanosome shape (controlled by PMEL) are independently regulated, and cylindrical but not spherical melanosomes enter apical processes.","method":"Morpholino knockdown of OA1 in zebrafish; electron microscopy; analysis of melanosome movement into apical processes","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — morpholino loss-of-function in a vertebrate model with EM morphometry, single lab","pmids":["25690007"],"is_preprint":false},{"year":2023,"finding":"GPR143 potentiates dopamine D2 receptor (DRD2) signaling through a direct physical interaction at the fifth transmembrane domain of GPR143. L-DOPA enhances the GPR143–DRD2 interaction and augments quinpirole-induced decrease in cAMP levels in cells co-expressing both receptors. A peptide disrupting the GPR143–DRD2 interaction mitigated DRD2-mediated behavioral effects in vivo. GPR143 selectively potentiates DRD2/D2L but not DRD1 or DRD3.","method":"Co-immunoprecipitation in cells co-expressing GPR143 and DRD2/DRD1/DRD3; cAMP assay; chimeric domain-swap analysis (GPR143 TM domains replaced with GPR37); intracerebroventricular peptide injection disrupting interaction; behavioral analysis in Gpr143-/y mice","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — chimeric mutagenesis + co-IP + cAMP signaling assay + in vivo peptide disruption + genetic knockout, multiple orthogonal methods establishing a specific TM5-mediated heteroreceptor complex mechanism","pmids":["36807226"],"is_preprint":false},{"year":2024,"finding":"GPR143 expressed in striatal cholinergic interneurons enhances DRD2-mediated haloperidol-induced catalepsy. Co-expression of GPR143 increases cell surface expression of DRD2, and L-DOPA application further enhances DRD2 surface expression. GPR143 regulates cholinergic interneuron firing pause duration.","method":"Cholinergic interneuron-specific Gpr143 conditional knockout (Chat-cre;Gpr143flox/y); striatal slice electrophysiology; surface DRD2 expression assay in CHO cells; ribosomal protein S6 phosphorylation in dorsolateral striatum; behavioral catalepsy assay","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — cell-type-specific conditional KO + electrophysiology + biochemical surface receptor assay, multiple orthogonal methods in a single study","pmids":["38286627"],"is_preprint":false},{"year":2023,"finding":"GPR143 interacts with adrenergic α1B receptor (ADRA1B) at the second transmembrane (TM2) domain interface. A TAT-TM2 peptide disrupts the GPR143–ADRA1B interaction and suppresses GPR143-mediated augmentation of phenylephrine-induced ERK phosphorylation.","method":"Chimeric domain-swap analysis (TM domains of GPR143 replaced with GPR37); co-immunoprecipitation of GPR143 and ADRA1B; ERK phosphorylation assay; TAT-fused TM2 peptide disruption in HEK293T cells","journal":"Biological & pharmaceutical bulletin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chimeric mutagenesis + co-IP + peptide disruption assay, single lab","pmids":["37394637"],"is_preprint":false},{"year":2019,"finding":"Overexpression of wild-type GPR143 (but not its disease-associated mutants) inhibits neurite outgrowth in NGF-treated PC12 cells. This inhibition is mitigated by the OA1 antagonist DOPA cyclohexyl ester and by knockdown of Gα13, placing Gα13 downstream of GPR143 in the neurite inhibition pathway.","method":"Overexpression of wild-type and mutant GPR143 in PC12 cells; neurite outgrowth measurement; pharmacological antagonism; Gα13 siRNA knockdown","journal":"Journal of pharmacological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (antagonist + siRNA) with gain-of-function overexpression and mutagenesis, single lab","pmids":["31606330"],"is_preprint":false},{"year":2024,"finding":"GPR143-induced inhibition of neurite outgrowth in PC12 cells is mediated via L-type calcium channels. Nifedipine (L-type Ca2+ channel blocker) restored neurite outgrowth inhibited by GPR143 overexpression to control levels, but had no effect in GPR143-knockdown cells.","method":"GPR143 overexpression and knockdown in PC12 cells; pharmacological inhibition with nifedipine, cilnidipine, flunarizine; neurite outgrowth quantification","journal":"Journal of pharmacological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection with KD controls, single lab, single method category","pmids":["39068034"],"is_preprint":false},{"year":2022,"finding":"L-DOPA promotes hippocampal neurogenesis through GPR143 in a dopamine-independent manner. L-DOPA at concentrations below those needed for dopamine signaling promoted neural stem/progenitor cell proliferation in wild-type but not Gpr143-/y mice under DOPA decarboxylase inhibition. Gpr143-/y mice show reduced hippocampal neurogenesis and increased depression-like behavior, rescued by re-expression of GPR143 in the dentate gyrus.","method":"Gpr143 knockout mice; DOPA decarboxylase inhibition; bromodeoxyuridine proliferation assay; viral re-expression of GPR143 in dentate gyrus; behavioral depression assays","journal":"Stem cells","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout + pharmacological decarboxylase inhibition + viral rescue, multiple orthogonal approaches establishing a GPR143-specific and dopamine-independent mechanism","pmids":["35257172"],"is_preprint":false},{"year":2024,"finding":"GPR143 oppositely regulates the two isoforms of the dopamine D2 receptor: it potentiates D2L (postsynaptic) function while suppressing D2S (presynaptic autoreceptor) function, as shown by differential effects on quinpirole-induced GSK3β phosphorylation in cells co-expressing each isoform with GPR143.","method":"CHO cell co-expression of GPR143 with D2L or D2S; GSK3β phosphorylation assay; dopamine release measurement (in vivo microdialysis); DA neuron-specific Gpr143 knockout (Dat-cre;Gpr143flox/y); haloperidol-induced catalepsy assay","journal":"Journal of pharmacological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based signaling assay with isoform specificity plus conditional knockout, single lab","pmids":["39179337"],"is_preprint":false},{"year":2021,"finding":"GPR143 (Gpr143) is involved in pulmonary artery vasoconstriction by coupling with adrenergic α1 receptor (ADRA1): L-DOPA pretreatment enhanced phenylephrine-induced vasoconstriction in wild-type but not Gpr143-/y rat pulmonary arteries. Gpr143-/y rats showed attenuated right ventricular systolic pressure in a monocrotaline-induced pulmonary hypertension model.","method":"Gpr143 gene-deficient rat generation; isolated pulmonary artery contractility assay; monocrotaline-induced PH model; right ventricular pressure measurement; pulmonary artery smooth muscle cell migration and proliferation assays","journal":"Journal of pharmacological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO rat model plus functional vascular assays, single lab","pmids":["35063136"],"is_preprint":false},{"year":2016,"finding":"Negative result: L-DOPA-induced ptosis in mice is GPR143-independent, as Gpr143-deficient mice showed ptosis to a similar extent as wild-type mice following L-DOPA administration under DOPA decarboxylase inhibition.","method":"Behavioral assay (ptosis scoring) in Gpr143-deficient and wild-type mice with DOPA decarboxylase inhibitor; dose-response analysis","journal":"Journal of pharmacological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO with controlled pharmacological treatment, single lab; informative negative result","pmids":["27622543"],"is_preprint":false}],"current_model":"GPR143 (OA1) is an intracellular 7-transmembrane GPCR localized to melanosomes and late endosomes/lysosomes via two unconventional sorting signals (a dileucine motif in the third cytosolic loop and a WE doublet in the C-tail); it is ubiquitinated and trafficked through the ESCRT machinery. Its principal endogenous ligand is L-DOPA (with dopamine acting as an antagonist), and upon activation it couples selectively to Gαi3 to regulate melanosome biogenesis—controlling both melanosome number (early stages) and size (stage IV)—and interacts with MART-1 as an escort protein and with melanoregulin linking it to the BLOC pathway. In the central nervous system, GPR143 forms physical complexes with dopamine D2 receptors (via its TM5 domain) and with adrenergic α1 receptors (via TM2) to potentiate their downstream signaling, modulates hippocampal neurogenesis and mood, and inhibits neurite outgrowth via Gα13 and L-type calcium channels. GPR143 also controls ESCRT-dependent exosome biogenesis by interacting with the ESCRT-0 subunit HRS to sort cargo such as EGFR and integrins into intraluminal vesicles."},"narrative":{"mechanistic_narrative":"GPR143 (OA1) is an intracellular seven-transmembrane G-protein-coupled receptor that governs melanosome biogenesis and serves more broadly as an L-DOPA sensor coupling endolysosomal organelle dynamics to G-protein signaling [PMID:18828673, PMID:17920058, PMID:16303920]. It is targeted to lysosomes and melanosomes by two independent, unconventional sorting signals—a dileucine motif in the third cytosolic loop and a WE doublet in the C-tail—both of which must be disrupted to redirect the receptor to the plasma membrane [PMID:16621890], and it adopts a 7TM topology with its C-terminus facing the cytoplasm [PMID:17920058]. L-DOPA is its endogenous agonist, triggering calcium influx and beta-arrestin recruitment, with dopamine acting as a competing antagonist [PMID:18828673]; arrestins in turn downregulate signaling [PMID:16524428]. Activated GPR143 couples selectively to Gαi3—not Gαi1 or Gαi2—and Gαi3 is the genetic downstream effector, since constitutively active Gαi3 rescues the melanosome phenotype of Oa1-null RPE [PMID:18378571, PMID:21931697, PMID:24098784]. Through this pathway it controls melanosome number at early maturation stages and melanosome size at stage IV, with loss of function producing giant macromelanosomes and optic pathway misrouting [PMID:11092754, PMID:16303920], and it acts via an MITF→PMEL transcriptional cascade and partners including the escort protein MART-1 and melanoregulin, which links it to the BLOC-2 pathway [PMID:19717472, PMID:24650003, PMID:22984402]. Mechanistically, GPR143 is ubiquitinated and sorted through the ESCRT machinery into intraluminal vesicles, selectively delaying PMEL-MVB delivery to lysosomes to commit cargo to melanosome biogenesis [PMID:21730137, PMID:24006264], and it more generally drives ESCRT-dependent exosome biogenesis by recruiting the ESCRT-0 subunit HRS to cargo such as EGFR, promoting cancer cell motility through integrin/FAK/Src signaling [PMID:36800996]. In the nervous system and vasculature it functions as an L-DOPA receptor that forms TM-domain-specific heteromers: a TM5 interaction potentiates dopamine D2 receptor signaling (potentiating D2L while suppressing D2S) and a TM2 interaction with adrenergic α1B receptor augments their signaling [PMID:24117106, PMID:36807226, PMID:37394637, PMID:39179337]. It promotes hippocampal neurogenesis and regulates mood in a dopamine-independent manner [PMID:35257172], and inhibits neurite outgrowth via Gα13 and L-type calcium channels [PMID:31606330, PMID:39068034]. Missense mutations cause ocular albinism either by ER retention/misfolding or by disrupting cytosolic-loop residues required for G-protein coupling [PMID:11115845].","teleology":[{"year":2000,"claim":"Establishing the physiological consequence of GPR143 loss showed that the receptor is required for melanosome size control and normal optic pathway wiring, defining the cellular basis of ocular albinism.","evidence":"Gene-targeted Oa1 knockout mouse with RPE electron microscopy and retinofugal pathway tracing","pmids":["11092754"],"confidence":"High","gaps":["Did not define the molecular signaling mechanism producing macromelanosomes","Mechanism of optic fiber misrouting not established"]},{"year":2000,"claim":"Systematic mutant analysis resolved how disease alleles fail, separating folding/trafficking defects from signaling defects and implicating the cytosolic loops in effector coupling.","evidence":"Expression of 19 missense mutants in COS-7 cells with localization and glycosylation readouts","pmids":["11115845"],"confidence":"High","gaps":["G-protein identity not yet known","No structural model of the coupling interface"]},{"year":2006,"claim":"Defining the receptor's intracellular addressing and constitutive signaling competence showed GPR143 is a bona fide GPCR delivered to lysosomes/melanosomes by two unconventional sorting signals and regulated by arrestins.","evidence":"Chimeric LAMP1 fusion constructs and mutagenesis for sorting; COS7 G-protein activation, phosphorylation, and arrestin co-IP","pmids":["16621890","16524428"],"confidence":"High","gaps":["Endogenous ligand not identified","Specific Gα subunit not defined"]},{"year":2007,"claim":"Direct topology mapping confirmed GPR143 spans the endolysosomal membrane seven times with a cytoplasmic C-terminus, validating its classification as an intracellular 7TM GPCR.","evidence":"HA-tag accessibility with selective permeabilization in COS-1 cells","pmids":["17920058"],"confidence":"High","gaps":["Does not address ligand access from the organelle lumen","No high-resolution structure"]},{"year":2008,"claim":"Identifying L-DOPA as the endogenous agonist and dopamine as antagonist established the receptor's pharmacology and linked activation to calcium, beta-arrestin, and an RPE PEDF autocrine loop.","evidence":"Radioligand binding, calcium and beta-arrestin assays, and PEDF secretion in RPE and transfected cells","pmids":["18828673"],"confidence":"High","gaps":["How a soluble metabolite reaches the intracellular receptor not defined","Did not link ligand binding to melanosome phenotypes in vivo"]},{"year":2008,"claim":"Coupling the receptor to a specific G protein, Gαi co-IP and Gαi3-knockout phenocopy placed Gαi3 in the OA1 melanosome pathway.","evidence":"Co-IP from melanocytes plus genetic epistasis comparing Gαi3-/- and Oa1-/- mice","pmids":["18378571"],"confidence":"High","gaps":["Did not distinguish among Gαi isoforms","Direct effector mechanism not yet shown"]},{"year":2011,"claim":"Refining and proving the effector relationship demonstrated Gαi3-selective binding and a reciprocal stability dependence, and ubiquitination/ESCRT studies revealed how the receptor is sorted into intraluminal vesicles.","evidence":"GST pull-down and co-IP across Gαi knockouts; ubiquitination assays with ESCRT depletion and EM","pmids":["21931697","21730137"],"confidence":"High","gaps":["The ubiquitin ligase acting on GPR143 not identified","Link between Gαi3 signaling and ESCRT sorting not integrated"]},{"year":2013,"claim":"Genetic rescue with constitutively active Gαi3 in Oa1-null RPE proved Gαi3 is the downstream effector, and parallel work showed OA1 activity selectively delays PMEL-MVB lysosomal delivery.","evidence":"Lentiviral Gαi3(Q204L) transgenesis with EM morphometry; OA1 wild-type/mutant expression in PMEL-HeLa cells with MVB and cargo assays","pmids":["24098784","24006264"],"confidence":"High","gaps":["How Gαi3 activity translates into MVB sorting decisions not resolved","Cargo selectivity mechanism not defined"]},{"year":2009,"claim":"Identifying protein partners that stabilize and route the receptor and organelle (MART-1, melanoregulin/BLOC-2) and the OA1→MITF→PMEL cascade connected GPR143 to the broader melanosome biogenesis machinery.","evidence":"Co-IP and siRNA with EM in melanocytes (MART-1); co-IP and genetic rescue (MREG); loss-of-function/rescue with MITF/PMEL readouts","pmids":["19717472","22984402","24650003"],"confidence":"Medium","gaps":["Whether MITF regulation is direct or downstream of signaling unresolved","Stoichiometry and order of partner assembly not defined"]},{"year":2014,"claim":"Demonstrating GPR143 acts as a functional L-DOPA receptor in defined CNS and vascular contexts extended its role beyond pigmentation to neurogenesis, mood, cardiovascular regulation, and neurite outgrowth.","evidence":"In vivo shRNA and antagonism in the NTS; Gpr143 knockout mice/rats with neurogenesis, behavioral, and pulmonary artery assays; PC12 neurite assays with Gα13 knockdown and L-type Ca2+ blockers","pmids":["24117106","35257172","35063136","31606330","39068034"],"confidence":"High","gaps":["G-protein/effector coupling differs across tissues and is incompletely mapped","Dopamine-independence mechanism in neurogenesis not fully resolved","A negative result shows L-DOPA-induced ptosis is GPR143-independent (PMID 27622543), bounding its pharmacology"]},{"year":2023,"claim":"Revealing TM-domain-specific heteroreceptor complexes showed GPR143 directly modulates other GPCRs—potentiating DRD2 via TM5 and ADRA1B via TM2—and that it drives ESCRT-dependent exosome biogenesis with cancer-relevant cargo via HRS.","evidence":"Chimeric domain-swap, co-IP, cAMP/ERK/GSK3β assays, in vivo peptide disruption and conditional knockouts (DRD2/ADRA1B); co-IP, exosome proteomics, and in vivo cancer models (HRS/EGFR)","pmids":["36807226","37394637","38286627","39179337","36800996"],"confidence":"High","gaps":["Structural basis of TM-interface heteromerization not solved","How a melanosomal receptor reaches the plasma membrane to engage cell-surface GPCRs not reconciled","Generality of HRS-cargo sorting beyond EGFR/integrins not established"]},{"year":null,"claim":"How a single intracellular L-DOPA receptor integrates G-protein coupling, ESCRT-dependent sorting, and surface heteroreceptor complexes into tissue-specific outputs remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of GPR143 alone or in complex","Mechanism reconciling melanosomal/endolysosomal localization with plasma-membrane heteromer function unknown","Unified model linking Gαi3, Gα13, and arrestin branches across tissues lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,16]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[18,20,24]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4,9]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[2,3,8]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[8,10]},{"term_id":"GO:0043226","term_label":"organelle","supporting_discovery_ids":[12,13]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[18,20,19]}],"pathway":[{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[12,13,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,18]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[8,9,10]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[16,23,21]}],"complexes":["BLOC-2 (via melanoregulin)","ESCRT-0 (via HRS)"],"partners":["GNAI3","MLANA","MREG","HGS","DRD2","ADRA1B","EGFR","GNA13"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P51810","full_name":"G-protein coupled receptor 143","aliases":["Ocular albinism type 1 protein"],"length_aa":404,"mass_kda":43.9,"function":"Receptor for tyrosine, L-DOPA and dopamine. After binding to L-DOPA, stimulates Ca(2+) influx into the cytoplasm, increases secretion of the neurotrophic factor SERPINF1 and relocalizes beta arrestin at the plasma membrane; this ligand-dependent signaling occurs through a G(q)-mediated pathway in melanocytic cells. Its activity is mediated by G proteins which activate the phosphoinositide signaling pathway. Also plays a role as an intracellular G protein-coupled receptor involved in melanosome biogenesis, organization and transport","subcellular_location":"Melanosome membrane; Lysosome membrane; Apical cell membrane","url":"https://www.uniprot.org/uniprotkb/P51810/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GPR143","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GPR143","total_profiled":1310},"omim":[{"mim_id":"606933","title":"TYROSINASE; TYR","url":"https://www.omim.org/entry/606933"},{"mim_id":"605513","title":"MELAN A; MLANA","url":"https://www.omim.org/entry/605513"},{"mim_id":"310700","title":"NYSTAGMUS 1, CONGENITAL, X-LINKED; NYS1","url":"https://www.omim.org/entry/310700"},{"mim_id":"300814","title":"NYSTAGMUS 6, CONGENITAL, X-LINKED; NYS6","url":"https://www.omim.org/entry/300814"},{"mim_id":"300808","title":"G PROTEIN-COUPLED RECEPTOR 143; GPR143","url":"https://www.omim.org/entry/300808"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nuclear bodies","reliability":"Additional"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"choroid plexus","ntpm":23.3}],"url":"https://www.proteinatlas.org/search/GPR143"},"hgnc":{"alias_symbol":[],"prev_symbol":["OA1"]},"alphafold":{"accession":"P51810","domains":[{"cath_id":"1.20.1070.10","chopping":"27-49_66-310","consensus_level":"medium","plddt":86.5232,"start":27,"end":310}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51810","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51810-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51810-F1-predicted_aligned_error_v6.png","plddt_mean":73.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GPR143","jax_strain_url":"https://www.jax.org/strain/search?query=GPR143"},"sequence":{"accession":"P51810","fasta_url":"https://rest.uniprot.org/uniprotkb/P51810.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51810/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51810"}},"corpus_meta":[{"pmid":"18828673","id":"PMC_18828673","title":"L-DOPA is an endogenous ligand for OA1.","date":"2008","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/18828673","citation_count":158,"is_preprint":false},{"pmid":"36800996","id":"PMC_36800996","title":"GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer metastasis.","date":"2023","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/36800996","citation_count":137,"is_preprint":false},{"pmid":"29343843","id":"PMC_29343843","title":"Cathelicidin-OA1, a novel antioxidant peptide identified from an amphibian, accelerates skin wound healing.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29343843","citation_count":101,"is_preprint":false},{"pmid":"8634705","id":"PMC_8634705","title":"Analysis of the OA1 gene reveals mutations in only one-third of patients with X-linked ocular albinism.","date":"1995","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8634705","citation_count":87,"is_preprint":false},{"pmid":"10330347","id":"PMC_10330347","title":"X-linked late-onset sensorineural deafness caused by a deletion involving OA1 and a novel gene containing WD-40 repeats.","date":"1999","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10330347","citation_count":83,"is_preprint":false},{"pmid":"11092754","id":"PMC_11092754","title":"Oa1 knock-out: new insights on the pathogenesis of ocular albinism type 1.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11092754","citation_count":77,"is_preprint":false},{"pmid":"19717472","id":"PMC_19717472","title":"The ocular albinism type 1 (OA1) G-protein-coupled receptor functions with MART-1 at early stages of melanogenesis to control melanosome identity and composition.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19717472","citation_count":76,"is_preprint":false},{"pmid":"11115845","id":"PMC_11115845","title":"Defective intracellular transport and processing of OA1 is a major cause of ocular albinism type 1.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11115845","citation_count":65,"is_preprint":false},{"pmid":"9529334","id":"PMC_9529334","title":"OA1 mutations and deletions in X-linked ocular albinism.","date":"1998","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9529334","citation_count":56,"is_preprint":false},{"pmid":"16303920","id":"PMC_16303920","title":"The ocular albinism type 1 (OA1) gene controls melanosome maturation and size.","date":"2005","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/16303920","citation_count":52,"is_preprint":false},{"pmid":"8364577","id":"PMC_8364577","title":"The genes for X-linked ocular albinism (OA1) and microphthalmia with linear skin defects (MLS): cloning and characterization of the critical regions.","date":"1993","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8364577","citation_count":52,"is_preprint":false},{"pmid":"17516023","id":"PMC_17516023","title":"Identification of a novel GPR143 mutation in a large Chinese family with congenital nystagmus as the most prominent and consistent manifestation.","date":"2007","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17516023","citation_count":48,"is_preprint":false},{"pmid":"25690007","id":"PMC_25690007","title":"Regulation of melanosome number, shape and movement in the zebrafish retinal pigment epithelium by OA1 and PMEL.","date":"2015","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/25690007","citation_count":48,"is_preprint":false},{"pmid":"16029416","id":"PMC_16029416","title":"The ocular albinism type 1 (OA1) protein and the evidence for an intracellular signal transduction system involved in melanosome biogenesis.","date":"2005","source":"Pigment cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16029416","citation_count":45,"is_preprint":false},{"pmid":"21541274","id":"PMC_21541274","title":"Screening of TYR, OCA2, GPR143, and MC1R in patients with congenital nystagmus, macular hypoplasia, and fundus hypopigmentation indicating albinism.","date":"2011","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/21541274","citation_count":42,"is_preprint":false},{"pmid":"16524428","id":"PMC_16524428","title":"The melanosomal/lysosomal protein OA1 has properties of a G protein-coupled receptor.","date":"2006","source":"Pigment cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16524428","citation_count":40,"is_preprint":false},{"pmid":"16621890","id":"PMC_16621890","title":"An unconventional dileucine-based motif and a novel cytosolic motif are required for the lysosomal and melanosomal targeting of OA1.","date":"2006","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/16621890","citation_count":38,"is_preprint":false},{"pmid":"16550551","id":"PMC_16550551","title":"Aberrant splicing in the ocular albinism type 1 gene (OA1/GPR143) is corrected in vitro by morpholino antisense oligonucleotides.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16550551","citation_count":37,"is_preprint":false},{"pmid":"11793467","id":"PMC_11793467","title":"New insights into ocular albinism type 1 (OA1): Mutations and polymorphisms of the OA1 gene.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11793467","citation_count":35,"is_preprint":false},{"pmid":"29761529","id":"PMC_29761529","title":"Pigmentation and vision: Is GPR143 in control?","date":"2018","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/29761529","citation_count":35,"is_preprint":false},{"pmid":"11095635","id":"PMC_11095635","title":"Expression pattern of the ocular albinism type 1 (Oa1) gene in the murine retinal pigment epithelium.","date":"2000","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/11095635","citation_count":35,"is_preprint":false},{"pmid":"11520764","id":"PMC_11520764","title":"Deletion in the OA1 gene in a family with congenital X linked nystagmus.","date":"2001","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/11520764","citation_count":35,"is_preprint":false},{"pmid":"24006264","id":"PMC_24006264","title":"Expression of OA1 limits the fusion of a subset of MVBs with lysosomes - a mechanism potentially involved in the initial biogenesis of melanosomes.","date":"2013","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/24006264","citation_count":34,"is_preprint":false},{"pmid":"27412401","id":"PMC_27412401","title":"Roles of OA1 octopamine receptor and Dop1 dopamine receptor in mediating appetitive and aversive reinforcement revealed by RNAi studies.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27412401","citation_count":34,"is_preprint":false},{"pmid":"21730137","id":"PMC_21730137","title":"The ocular albinism type 1 (OA1) GPCR is ubiquitinated and its traffic requires endosomal sorting complex responsible for transport (ESCRT) function.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21730137","citation_count":31,"is_preprint":false},{"pmid":"11214907","id":"PMC_11214907","title":"Diverse prevalence of large deletions within the OA1 gene in ocular albinism type 1 patients from Europe and North America.","date":"2001","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11214907","citation_count":28,"is_preprint":false},{"pmid":"18378571","id":"PMC_18378571","title":"Involvement of OA1, an intracellular GPCR, and G alpha i3, its binding protein, in melanosomal biogenesis and optic pathway formation.","date":"2008","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/18378571","citation_count":28,"is_preprint":false},{"pmid":"8889556","id":"PMC_8889556","title":"Cloning of the murine homolog of the ocular albinism type 1 (OA1) gene: sequence, genomic structure, and expression analysis in pigment cells.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889556","citation_count":28,"is_preprint":false},{"pmid":"31632270","id":"PMC_31632270","title":"l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31632270","citation_count":27,"is_preprint":false},{"pmid":"25601010","id":"PMC_25601010","title":"Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs.","date":"2015","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/25601010","citation_count":26,"is_preprint":false},{"pmid":"26061757","id":"PMC_26061757","title":"Deep intronic GPR143 mutation in a Japanese family with ocular albinism.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26061757","citation_count":25,"is_preprint":false},{"pmid":"24117106","id":"PMC_24117106","title":"The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii.","date":"2014","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24117106","citation_count":25,"is_preprint":false},{"pmid":"24650003","id":"PMC_24650003","title":"Melanosome-autonomous regulation of size and number: the OA1 receptor sustains PMEL expression.","date":"2014","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/24650003","citation_count":23,"is_preprint":false},{"pmid":"18523664","id":"PMC_18523664","title":"Identification of a novel GPR143 deletion in a Chinese family with X-linked congenital nystagmus.","date":"2008","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/18523664","citation_count":23,"is_preprint":false},{"pmid":"8921399","id":"PMC_8921399","title":"Isolation and characterization of a mouse homolog of the X-linked ocular albinism (OA1) gene.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8921399","citation_count":22,"is_preprint":false},{"pmid":"18978956","id":"PMC_18978956","title":"Novel GPR143 mutations and clinical characteristics in six Chinese families with X-linked ocular albinism.","date":"2008","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/18978956","citation_count":21,"is_preprint":false},{"pmid":"12538723","id":"PMC_12538723","title":"Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12538723","citation_count":21,"is_preprint":false},{"pmid":"26160353","id":"PMC_26160353","title":"GPR143 Gene Mutations in Five Chinese Families with X-linked Congenital Nystagmus.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26160353","citation_count":20,"is_preprint":false},{"pmid":"8870926","id":"PMC_8870926","title":"Mental retardation in a boy with an interstitial deletion at Xp22.3 involving STS, KAL1, and OA1: implication for the MRX locus.","date":"1996","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8870926","citation_count":20,"is_preprint":false},{"pmid":"12515581","id":"PMC_12515581","title":"Identification of three novel OA1 gene mutations identified in three families misdiagnosed with congenital nystagmus and carrier status determination by real-time quantitative PCR assay.","date":"2003","source":"BMC genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12515581","citation_count":19,"is_preprint":false},{"pmid":"17920058","id":"PMC_17920058","title":"The ocular albinism type 1 gene product, OA1, spans intracellular membranes 7 times.","date":"2007","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/17920058","citation_count":17,"is_preprint":false},{"pmid":"9457748","id":"PMC_9457748","title":"Clinical and molecular characterization of a family affected with X-linked ocular albinism (OA1).","date":"1997","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9457748","citation_count":16,"is_preprint":false},{"pmid":"21931697","id":"PMC_21931697","title":"Specific interaction of Gαi3 with the Oa1 G-protein coupled receptor controls the size and density of melanosomes in retinal pigment epithelium.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21931697","citation_count":16,"is_preprint":false},{"pmid":"2280973","id":"PMC_2280973","title":"Localization of the X-linked ocular albinism gene (OA1) between DXS278/DXS237 and DXS143/DXS16 by linkage analysis.","date":"1990","source":"Ophthalmic paediatrics and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2280973","citation_count":16,"is_preprint":false},{"pmid":"19610097","id":"PMC_19610097","title":"Iris hyperpigmentation in a Chinese family with ocular albinism and the GPR143 mutation.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19610097","citation_count":16,"is_preprint":false},{"pmid":"19390656","id":"PMC_19390656","title":"A novel GPR143 duplication mutation in a Chinese family with X-linked congenital nystagmus.","date":"2009","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/19390656","citation_count":14,"is_preprint":false},{"pmid":"17163525","id":"PMC_17163525","title":"A male infant with a 9.6 Mb terminal Xp deletion including the OA1 locus: Limit of viability of Xp deletions in males.","date":"2007","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/17163525","citation_count":14,"is_preprint":false},{"pmid":"21423867","id":"PMC_21423867","title":"A novel GPR143 splicing mutation in a Chinese family with X-linked congenital nystagmus.","date":"2011","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/21423867","citation_count":13,"is_preprint":false},{"pmid":"16646960","id":"PMC_16646960","title":"Eight previously unidentified mutations found in the OA1 ocular albinism gene.","date":"2006","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16646960","citation_count":13,"is_preprint":false},{"pmid":"32763057","id":"PMC_32763057","title":"Genetic associations of single nucleotide polymorphisms in the l-DOPA receptor (GPR143) gene with severity of nicotine dependence in Japanese individuals, and attenuation of nicotine reinforcement in Gpr143 gene-deficient mice.","date":"2020","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32763057","citation_count":12,"is_preprint":false},{"pmid":"23091330","id":"PMC_23091330","title":"A case of 9.7 Mb terminal Xp deletion including OA1 locus associated with contiguous gene syndrome.","date":"2012","source":"Journal of Korean medical science","url":"https://pubmed.ncbi.nlm.nih.gov/23091330","citation_count":12,"is_preprint":false},{"pmid":"36807226","id":"PMC_36807226","title":"Coupling between GPR143 and dopamine D2 receptor is required for selective potentiation of dopamine D2 receptor function by L-3,4-dihydroxyphenylalanine in the dorsal striatum.","date":"2023","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36807226","citation_count":11,"is_preprint":false},{"pmid":"22916221","id":"PMC_22916221","title":"A novel nonsense mutation of the GPR143 gene identified in a Chinese pedigree with ocular albinism.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22916221","citation_count":11,"is_preprint":false},{"pmid":"12868035","id":"PMC_12868035","title":"Mutational analysis of the OA1 gene in ocular albinism.","date":"2003","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12868035","citation_count":11,"is_preprint":false},{"pmid":"26778432","id":"PMC_26778432","title":"Role of ocular albinism type 1 (OA1) GPCR in Asian gypsy moth development and transcriptional expression of heat-shock protein genes.","date":"2015","source":"Pesticide biochemistry and physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26778432","citation_count":11,"is_preprint":false},{"pmid":"31884582","id":"PMC_31884582","title":"GPR143 Signaling and Retinal Degeneration.","date":"2019","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/31884582","citation_count":10,"is_preprint":false},{"pmid":"37945816","id":"PMC_37945816","title":"Investigation of GPR143 as a promising novel marker for the progression of skin cutaneous melanoma through bioinformatic analyses and cell experiments.","date":"2023","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/37945816","citation_count":10,"is_preprint":false},{"pmid":"21938455","id":"PMC_21938455","title":"Structural insights into human GPCR protein OA1: a computational perspective.","date":"2011","source":"Journal of molecular modeling","url":"https://pubmed.ncbi.nlm.nih.gov/21938455","citation_count":10,"is_preprint":false},{"pmid":"25108060","id":"PMC_25108060","title":"Localization of ocular albinism-1 gene product GPR143 in the rat central nervous system.","date":"2014","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/25108060","citation_count":10,"is_preprint":false},{"pmid":"35257172","id":"PMC_35257172","title":"L-DOPA-Induced Neurogenesis in the Hippocampus Is Mediated Through GPR143, a Distinct Mechanism of Dopamine.","date":"2022","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/35257172","citation_count":9,"is_preprint":false},{"pmid":"22984402","id":"PMC_22984402","title":"Melanoregulin, product of the dsu locus, links the BLOC-pathway and OA1 in organelle biogenesis.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22984402","citation_count":9,"is_preprint":false},{"pmid":"16754205","id":"PMC_16754205","title":"Scanning the ocular albinism 1 (OA1) gene for polymorphisms in congenital nystagmus by DHPLC.","date":"2006","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16754205","citation_count":8,"is_preprint":false},{"pmid":"38286627","id":"PMC_38286627","title":"Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons.","date":"2024","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38286627","citation_count":7,"is_preprint":false},{"pmid":"27367509","id":"PMC_27367509","title":"Simultaneous Expression of ABCA4 and GPR143 Mutations: A Complex Phenotypic Manifestation.","date":"2016","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/27367509","citation_count":7,"is_preprint":false},{"pmid":"24098784","id":"PMC_24098784","title":"A constitutively active Gαi3 protein corrects the abnormal retinal pigment epithelium phenotype of Oa1-/- mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24098784","citation_count":7,"is_preprint":false},{"pmid":"28339057","id":"PMC_28339057","title":"GPR143 mutations in Chinese patients with ocular albinism type 1.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28339057","citation_count":7,"is_preprint":false},{"pmid":"12180081","id":"PMC_12180081","title":"Diagnostic DNA testing for X-linked ocular albinism (OA1) with a hierarchical mutation screening protocol.","date":"2002","source":"Genetic testing","url":"https://pubmed.ncbi.nlm.nih.gov/12180081","citation_count":7,"is_preprint":false},{"pmid":"24526317","id":"PMC_24526317","title":"Macular optical coherence tomography findings and GPR143 mutations in patients with ocular albinism.","date":"2014","source":"International ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/24526317","citation_count":7,"is_preprint":false},{"pmid":"22486324","id":"PMC_22486324","title":"GPR143 gene mutation analysis in pediatric patients with albinism.","date":"2012","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22486324","citation_count":6,"is_preprint":false},{"pmid":"35686978","id":"PMC_35686978","title":"CRISPR-AsCas12a Efficiently Corrects a GPR143 Intronic Mutation in Induced Pluripotent Stem Cells from an Ocular Albinism Patient.","date":"2022","source":"The CRISPR journal","url":"https://pubmed.ncbi.nlm.nih.gov/35686978","citation_count":6,"is_preprint":false},{"pmid":"31746431","id":"PMC_31746431","title":"A novel GPR143 mutation in a Chinese family with X‑linked ocular albinism type 1.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/31746431","citation_count":6,"is_preprint":false},{"pmid":"31574285","id":"PMC_31574285","title":"Evaluation of the iris thickness changes for the Chinese families with GPR143 gene mutations.","date":"2019","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/31574285","citation_count":6,"is_preprint":false},{"pmid":"15965158","id":"PMC_15965158","title":"Abnormal crossing of the optic fibres shown by evoked magnetic fields in patients with ocular albinism with a novel mutation in the OA1 gene.","date":"2005","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/15965158","citation_count":6,"is_preprint":false},{"pmid":"24301936","id":"PMC_24301936","title":"A novel splicing site mutation of the GPR143 gene in a Chinese X-linked ocular albinism pedigree.","date":"2013","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/24301936","citation_count":6,"is_preprint":false},{"pmid":"30555098","id":"PMC_30555098","title":"Identification of a novel GPR143 mutation in X-linked ocular albinism with marked intrafamilial phenotypic variability.","date":"2018","source":"Journal of genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30555098","citation_count":6,"is_preprint":false},{"pmid":"34346269","id":"PMC_34346269","title":"GPR143 genotypic and ocular phenotypic characterisation in a Chinese cohort with ocular albinism.","date":"2021","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34346269","citation_count":5,"is_preprint":false},{"pmid":"39509688","id":"PMC_39509688","title":"L-DOPA Promotes Functional Proliferation Through GPR143, Specific L-DOPA Receptor of Astrocytes.","date":"2024","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/39509688","citation_count":5,"is_preprint":false},{"pmid":"31606330","id":"PMC_31606330","title":"Overexpression of the gene product of ocular albinism 1 (GPR143/OA1) but not its mutant forms inhibits neurite outgrowth in PC12 cells.","date":"2019","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31606330","citation_count":4,"is_preprint":false},{"pmid":"30590075","id":"PMC_30590075","title":"Immunoreactivity of a G protein-coupled l-DOPA receptor GPR143, in Lewy bodies.","date":"2018","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/30590075","citation_count":4,"is_preprint":false},{"pmid":"35063136","id":"PMC_35063136","title":"Right ventricular overloading is attenuated in monocrotaline-induced pulmonary hypertension model rats with a disrupted Gpr143 gene, the gene that encodes the 3,4-l-dihydroxyphenyalanine (l-DOPA) receptor.","date":"2021","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35063136","citation_count":4,"is_preprint":false},{"pmid":"33785018","id":"PMC_33785018","title":"Identification of a novel GPR143 mutation in a large Chinese family with isolated foveal hypoplasia.","date":"2021","source":"BMC ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/33785018","citation_count":4,"is_preprint":false},{"pmid":"32896531","id":"PMC_32896531","title":"Distribution of mRNA for GPR143, a receptor of 3,4-L-dihydroxyphenylalanine, and of immunoreactivities for nicotinic acetylcholine receptors in the nigrostriatal and mesolimbic regions.","date":"2020","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/32896531","citation_count":4,"is_preprint":false},{"pmid":"35951714","id":"PMC_35951714","title":"Macular Findings in Carriers of Ocular Albinism With a Novel GPR143 Mutation.","date":"2022","source":"Ophthalmic surgery, lasers & imaging retina","url":"https://pubmed.ncbi.nlm.nih.gov/35951714","citation_count":4,"is_preprint":false},{"pmid":"27622543","id":"PMC_27622543","title":"l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice.","date":"2016","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27622543","citation_count":4,"is_preprint":false},{"pmid":"30513407","id":"PMC_30513407","title":"Generation of a human Ocular Albinism type 1 iPSC line, SEIi001-A, with a mutation in GPR143.","date":"2018","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30513407","citation_count":4,"is_preprint":false},{"pmid":"36649556","id":"PMC_36649556","title":"Mutation of GPR143 Associated With Ocular Albinism Type 1, Intellectual Disability, and Schizophrenia: The Complex Biological and Social Interactions Between Genetic Syndromes and Mental Illness.","date":"2023","source":"Journal of psychiatric practice","url":"https://pubmed.ncbi.nlm.nih.gov/36649556","citation_count":3,"is_preprint":false},{"pmid":"34445325","id":"PMC_34445325","title":"Blue Cone Monochromatism with Foveal Hypoplasia Caused by the Concomitant Effect of Variants in OPN1LW/OPN1MW and GPR143 Genes.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34445325","citation_count":3,"is_preprint":false},{"pmid":"28849423","id":"PMC_28849423","title":"A Novel Acetaldehyde Dehydrogenase with Salicylaldehyde Dehydrogenase Activity from Rhodococcus ruber Strain OA1.","date":"2017","source":"Current microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28849423","citation_count":3,"is_preprint":false},{"pmid":"27733339","id":"PMC_27733339","title":"Expression and localization of GPR143 in sheep skin.","date":"2016","source":"Yi chuan = Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/27733339","citation_count":2,"is_preprint":false},{"pmid":"39179337","id":"PMC_39179337","title":"Opposite regulation by L-DOPA receptor GPR143 of the long and short forms of the dopamine D2 receptors.","date":"2024","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39179337","citation_count":2,"is_preprint":false},{"pmid":"19604113","id":"PMC_19604113","title":"GPR143 mutational analysis in two Italian families with X-linked ocular albinism.","date":"2009","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/19604113","citation_count":2,"is_preprint":false},{"pmid":"31103373","id":"PMC_31103373","title":"Ocular albinism with mutation in GPR143: Findings in wide-field autofluorescence and optical coherence tomography.","date":"2019","source":"Archivos de la Sociedad Espanola de Oftalmologia","url":"https://pubmed.ncbi.nlm.nih.gov/31103373","citation_count":2,"is_preprint":false},{"pmid":"20649618","id":"PMC_20649618","title":"Identification of a novel deletion in the OA1 gene: report of the first Spanish family with X-linked ocular albinism.","date":"2010","source":"Clinical & experimental ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/20649618","citation_count":2,"is_preprint":false},{"pmid":"37394637","id":"PMC_37394637","title":"L-DOPA Receptor GPR143 Functionally Couples with Adrenergic α1B Receptor at the Second Transmembrane Interface.","date":"2023","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/37394637","citation_count":1,"is_preprint":false},{"pmid":"41510670","id":"PMC_41510670","title":"Disruption of the l-DOPA Receptor Gpr143/OA1-Gene in Mice Creates a Unique Mixed Psychosis-Like Phenotype.","date":"2026","source":"Neuropsychopharmacology reports","url":"https://pubmed.ncbi.nlm.nih.gov/41510670","citation_count":1,"is_preprint":false},{"pmid":"39068034","id":"PMC_39068034","title":"l-DOPA receptor GPR143 inhibits neurite outgrowth via L-type calcium channels in PC12 cells.","date":"2024","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39068034","citation_count":1,"is_preprint":false},{"pmid":"38222445","id":"PMC_38222445","title":"GPR143 mutations in an X-linked infantile nystagmus syndrome cohort in Southeast China.","date":"2023","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/38222445","citation_count":1,"is_preprint":false},{"pmid":"37257945","id":"PMC_37257945","title":"Involvement of the L-DOPA receptor GPR143 in acute and chronic actions of methylphenidate.","date":"2023","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37257945","citation_count":1,"is_preprint":false},{"pmid":"38648460","id":"PMC_38648460","title":"Differences of ocular oscillations and neuro-retinal structures in patients with nystagmus caused by GPR143 and FRMD7 gene variants.","date":"2024","source":"Indian journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/38648460","citation_count":1,"is_preprint":false},{"pmid":"7759088","id":"PMC_7759088","title":"Intragenic TaqI restriction fragment length polymorphism (RFLP) in CICN4, between the loci for X-linked ocular albinism (OA1) and microphthalmia with linear skin defects syndrome (MLS).","date":"1995","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7759088","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48054,"output_tokens":7414,"usd":0.127686,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16716,"output_tokens":4535,"usd":0.098477,"stage2_stop_reason":"end_turn"},"total_usd":0.226163,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"L-DOPA is an endogenous ligand for OA1/GPR143. Radiolabeled ligand binding confirmed a single, saturable binding site for L-DOPA. OA1 activation by L-DOPA triggers intracellular calcium influx and beta-arrestin recruitment. Dopamine competed with L-DOPA for the OA1 binding site, suggesting it acts as an antagonist. OA1 stimulation in RPE with L-DOPA results in increased PEDF secretion, forming an autocrine loop with tyrosinase.\",\n      \"method\": \"Radiolabeled ligand binding assay, intracellular calcium influx measurement, beta-arrestin recruitment assay, PEDF secretion assay, tyrosinase inhibition experiments in RPE cells and transfected cell lines\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal in vitro assays (radioligand binding, second messenger, beta-arrestin) in one rigorous study establishing ligand identity and receptor activation mechanism\",\n      \"pmids\": [\"18828673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"OA1 expressed in COS7 cells activates heterotrimeric G proteins spontaneously. OA1 mutants with missense mutation or deletion in the third cytosolic loop lack this ability. OA1 is phosphorylated, colocalizes and coprecipitates with arrestins, and arrestins downregulate OA1 signaling by reducing its expression levels.\",\n      \"method\": \"Heterologous expression in COS7 cells, G protein activation assay, co-immunoprecipitation with arrestins, colocalization immunofluorescence, phosphorylation assay\",\n      \"journal\": \"Pigment cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (G protein activation, co-IP, phosphorylation, mutagenesis) in a single study establishing GPCR functional properties\",\n      \"pmids\": [\"16524428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"OA1 intracellular targeting to lysosomes and melanosomes requires two separate sorting signals: an unconventional dileucine motif in the third cytosolic loop and a novel tryptophan-glutamic acid (WE) doublet in the C-terminal tail. Both motifs must be simultaneously mutated to redirect OA1 to the plasma membrane, indicating they independently drive intracellular targeting.\",\n      \"method\": \"Chimeric protein constructs (OA1 cytosolic domains fused to LAMP1 lumenal/TM domains), missense and deletion mutagenesis, subcellular localization by immunofluorescence in melanocytic and non-melanocytic cells\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution with chimeric proteins plus mutagenesis plus functional localization readout, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"16621890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"OA1, properly localized to intracellular lysosomal organelles, spans the membrane seven times with its C-terminus directed to the cytoplasm, confirming its topology as an intracellular 7-transmembrane GPCR.\",\n      \"method\": \"HA-tag insertion into predicted cytosolic/luminal regions, selective plasma membrane permeabilization leaving endolysosomal membranes intact, immunofluorescence accessibility assay in COS-1 cells\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct membrane topology mapping by selective permeabilization and HA-tag accessibility, rigorous controls with LAMP1 reporter\",\n      \"pmids\": [\"17920058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"OA1 interacts biochemically with the premelanosomal protein MART-1. MART-1 loss by siRNA reduces OA1 stability and causes similar defects in premelanosome biogenesis and composition, indicating MART-1 acts as an escort protein for OA1. OA1 loss of function leads to decreased pigmentation and formation of enlarged aberrant premelanosomes with disorganized fibrillar structures displaying mislocalized mature melanosome and lysosome membrane proteins.\",\n      \"method\": \"siRNA inactivation of OA1 and MART-1 in human pigmented melanocytic cells, co-immunoprecipitation, electron microscopy of melanosome ultrastructure, immunofluorescence of melanosomal protein localization\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal biochemical interaction plus functional KD phenotypes with multiple orthogonal readouts (co-IP, EM, IF) in a single study\",\n      \"pmids\": [\"19717472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"OA1 coimmunoprecipitates with the Gαi subunit of heterotrimeric G proteins from human melanocyte extracts. Gαi3-deficient mice phenocopy Oa1-deficient mice with reduced melanosome density, enlarged melanosomes, and reduced ipsilateral retinofugal projections, placing Gαi3 in the same pathway as OA1.\",\n      \"method\": \"Co-immunoprecipitation from human melanocyte extracts; genetic epistasis using Gαi3-/- and Oa1-/- mouse models; light and electron microscopy of RPE melanosomes; retrograde labeling of optic pathway\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP plus genetic epistasis with knockout mice and multiple phenotypic readouts, independently supported by subsequent studies\",\n      \"pmids\": [\"18378571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Among Gαi subfamily members, Gαi3 specifically binds to Oa1. GST pull-down and immunoprecipitation assays demonstrate that only Gαi3 (not Gαi1 or Gαi2) interacts with Oa1. Gαi3 expression is barely detectable in Oa1-/- RPE, indicating Oa1 is required for Gαi3 stability in this tissue.\",\n      \"method\": \"GST pull-down, co-immunoprecipitation, Western blotting in Gαi1-/-, Gαi2-/-, Gαi3-/- and double knockout mice, RPE morphometry by electron microscopy\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct biochemical binding assays (GST pull-down + co-IP) with multiple genetic controls establishing specificity of the Oa1–Gαi3 interaction\",\n      \"pmids\": [\"21931697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A constitutively active Gαi3 (Q204L) expressed in the RPE of Oa1-/- mice rescues the normal melanosomal phenotype, restoring higher melanosome density and normal small melanosome size, demonstrating that Gαi3 is the downstream effector of Oa1 in melanosome biogenesis.\",\n      \"method\": \"Lentiviral transgenesis of constitutively active Gαi3(Q204L) in Oa1-/- RPE; electron microscopy morphometry; PCR, Southern, Western blot, confocal microscopy for transgene confirmation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue experiment with constitutively active downstream effector, rigorous morphometric quantification by EM\",\n      \"pmids\": [\"24098784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"OA1 is ubiquitinated, and its intracellular sorting and degradation require functional ESCRT-0, -I, and -III components. OA1 ubiquitination is specifically required for its targeting to intraluminal vesicles of multivesicular endosomes, regulating the balance between degradation and delivery to melanosomes.\",\n      \"method\": \"Biochemical ubiquitination assays, overexpression and siRNA depletion of ESCRT subunits, morphological analysis by immunofluorescence and electron microscopy\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical (ubiquitination assay) plus functional (ESCRT depletion/overexpression) plus morphological readouts, multiple orthogonal methods in one study\",\n      \"pmids\": [\"21730137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GPR143 controls ESCRT-dependent exosome biogenesis by interacting with HRS (ESCRT-0 subunit) and promoting HRS association with cargo proteins such as EGFR, enabling selective protein sorting into intraluminal vesicles in multivesicular bodies. GPR143-driven exosome secretion carries integrin signaling proteins and promotes cancer cell motility/invasion through the integrin/FAK/Src pathway.\",\n      \"method\": \"Co-immunoprecipitation of GPR143 with HRS and EGFR; quantitative proteomics and RNA profiling of exosomes; gain- and loss-of-function in mouse cancer models; cell motility/invasion assays\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, quantitative proteomics, in vivo gain/loss-of-function, multiple orthogonal methods establishing a new mechanistic role\",\n      \"pmids\": [\"36800996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"OA1 expression (but not signaling-deficient OA1 mutants) increases MVB numbers and inhibits lysosomal delivery of PMEL-containing MVBs without affecting EGFR-containing MVB degradation, indicating OA1 activity selectively delays PMEL-MVB fusion with lysosomes to allow commitment to melanosome biogenesis.\",\n      \"method\": \"OA1 wild-type and inactivating mutant expression in HeLa cells expressing PMEL; quantification of MVB numbers by electron microscopy; EGFR degradation assay; PMEL delivery to lysosome assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional mutagenesis with EM morphometry and biochemical cargo-tracking assays, multiple orthogonal methods distinguishing OA1-specific from non-specific MVB effects\",\n      \"pmids\": [\"24006264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Missense mutations in OA1 cause two distinct biochemical defects: ~60% cause ER retention with defective glycosylation (protein misfolding), while ~40% traffic normally but cluster in the second and third cytosolic loops critical for G protein coupling and effector activation.\",\n      \"method\": \"Expression of 19 missense mutants in COS-7 cells, analysis of subcellular distribution by immunofluorescence, glycosylation analysis by biochemical methods\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic analysis of 19 mutants with two orthogonal readouts (localization + glycosylation) establishing structure-function relationships\",\n      \"pmids\": [\"11115845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Oa1 knockout mice display giant melanosomes (macromelanosomes) in RPE formed by abnormal growth of single melanosomes rather than fusion, and show reduced size of the uncrossed retinofugal pathway (optic fiber misrouting), establishing Oa1 as required for melanosome size regulation and normal optic pathway development.\",\n      \"method\": \"Gene targeting knockout mouse; electron microscopy of RPE; retrograde labeling of retinofugal pathway; ophthalmologic examination\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with EM ultrastructural analysis and neuroanatomical pathway tracing, replicating the human disease phenotype\",\n      \"pmids\": [\"11092754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Oa1 controls melanosome biogenesis at two stages: at early maturation stages it controls the abundance (number) of melanosomes in RPE cells, and at later stages (stage IV) it controls organelle size. This was established using double-knockout mice combining Oa1 null with either Tyr or Matp mutations that block melanosome maturation at stages II and III respectively.\",\n      \"method\": \"Genetic epistasis with double-knockout mice (Oa1-/-;Tyr(c-2J) and Oa1-/-;Matp(uw)); electron microscopy morphometry; immunohistochemistry of tyrosinase activity\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — double-knockout genetic epistasis with EM morphometry, cleanly placing OA1 function at two distinct steps of melanosome maturation\",\n      \"pmids\": [\"16303920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"OA1 loss of function reduces basal and α-MSH/cAMP-induced MITF expression, which in turn reduces PMEL expression without affecting tyrosinase or melanin levels. OA1 re-expression rescues melanosome biogenesis and activates MITF expression, establishing an OA1→MITF→PMEL transcriptional cascade for melanosome quality control.\",\n      \"method\": \"OA1 loss-of-function and rescue in melanocytes; qRT-PCR and Western blot for MITF and PMEL; α-MSH stimulation assays; melanosome morphometry\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional rescue with molecular pathway readouts, single lab, two orthogonal methods\",\n      \"pmids\": [\"24650003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Melanoregulin (MREG) interacts with both BLOC-2 complex members and Oa1, linking the BLOC pathway to Oa1 in melanosome size regulation. Transgenic overexpression of melanoregulin in Oa1-knockout mice corrects macromelanosome size in RPE, while MREG loss enlarges micromelanosomes in BLOC-2 mutants.\",\n      \"method\": \"Co-immunoprecipitation of MREG with Oa1 and BLOC-2 members; Oa1 knockout mouse crossed with MREG transgenic mouse; electron microscopy of RPE melanosomes\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus genetic rescue experiment, single lab\",\n      \"pmids\": [\"22984402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"OA1/GPR143 functions as a receptor for L-DOPA in the nucleus tractus solitarii (NTS) in vivo. OA1 shRNA knockdown in the NTS blocked depressor and bradycardic responses to microinjected L-DOPA but not to glutamate. A competitive OA1 antagonist (DOPA cyclohexyl ester) suppressed phenylephrine-induced bradycardic responses.\",\n      \"method\": \"Immunohistochemistry of OA1 in NTS; adenoviral shRNA knockdown of OA1 in NTS; blood pressure and heart rate measurements after DOPA microinjection in anesthetized rats; pharmacological antagonism\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function (shRNA) with pharmacological antagonism, two orthogonal approaches establishing receptor function in a defined CNS nucleus\",\n      \"pmids\": [\"24117106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Morpholino-mediated knockdown of OA1 in zebrafish RPE induces a major reduction in melanosome number, recapitulating the mammalian disease. Melanosome number (controlled by OA1) and melanosome shape (controlled by PMEL) are independently regulated, and cylindrical but not spherical melanosomes enter apical processes.\",\n      \"method\": \"Morpholino knockdown of OA1 in zebrafish; electron microscopy; analysis of melanosome movement into apical processes\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — morpholino loss-of-function in a vertebrate model with EM morphometry, single lab\",\n      \"pmids\": [\"25690007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GPR143 potentiates dopamine D2 receptor (DRD2) signaling through a direct physical interaction at the fifth transmembrane domain of GPR143. L-DOPA enhances the GPR143–DRD2 interaction and augments quinpirole-induced decrease in cAMP levels in cells co-expressing both receptors. A peptide disrupting the GPR143–DRD2 interaction mitigated DRD2-mediated behavioral effects in vivo. GPR143 selectively potentiates DRD2/D2L but not DRD1 or DRD3.\",\n      \"method\": \"Co-immunoprecipitation in cells co-expressing GPR143 and DRD2/DRD1/DRD3; cAMP assay; chimeric domain-swap analysis (GPR143 TM domains replaced with GPR37); intracerebroventricular peptide injection disrupting interaction; behavioral analysis in Gpr143-/y mice\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — chimeric mutagenesis + co-IP + cAMP signaling assay + in vivo peptide disruption + genetic knockout, multiple orthogonal methods establishing a specific TM5-mediated heteroreceptor complex mechanism\",\n      \"pmids\": [\"36807226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GPR143 expressed in striatal cholinergic interneurons enhances DRD2-mediated haloperidol-induced catalepsy. Co-expression of GPR143 increases cell surface expression of DRD2, and L-DOPA application further enhances DRD2 surface expression. GPR143 regulates cholinergic interneuron firing pause duration.\",\n      \"method\": \"Cholinergic interneuron-specific Gpr143 conditional knockout (Chat-cre;Gpr143flox/y); striatal slice electrophysiology; surface DRD2 expression assay in CHO cells; ribosomal protein S6 phosphorylation in dorsolateral striatum; behavioral catalepsy assay\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific conditional KO + electrophysiology + biochemical surface receptor assay, multiple orthogonal methods in a single study\",\n      \"pmids\": [\"38286627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GPR143 interacts with adrenergic α1B receptor (ADRA1B) at the second transmembrane (TM2) domain interface. A TAT-TM2 peptide disrupts the GPR143–ADRA1B interaction and suppresses GPR143-mediated augmentation of phenylephrine-induced ERK phosphorylation.\",\n      \"method\": \"Chimeric domain-swap analysis (TM domains of GPR143 replaced with GPR37); co-immunoprecipitation of GPR143 and ADRA1B; ERK phosphorylation assay; TAT-fused TM2 peptide disruption in HEK293T cells\",\n      \"journal\": \"Biological & pharmaceutical bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chimeric mutagenesis + co-IP + peptide disruption assay, single lab\",\n      \"pmids\": [\"37394637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Overexpression of wild-type GPR143 (but not its disease-associated mutants) inhibits neurite outgrowth in NGF-treated PC12 cells. This inhibition is mitigated by the OA1 antagonist DOPA cyclohexyl ester and by knockdown of Gα13, placing Gα13 downstream of GPR143 in the neurite inhibition pathway.\",\n      \"method\": \"Overexpression of wild-type and mutant GPR143 in PC12 cells; neurite outgrowth measurement; pharmacological antagonism; Gα13 siRNA knockdown\",\n      \"journal\": \"Journal of pharmacological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (antagonist + siRNA) with gain-of-function overexpression and mutagenesis, single lab\",\n      \"pmids\": [\"31606330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GPR143-induced inhibition of neurite outgrowth in PC12 cells is mediated via L-type calcium channels. Nifedipine (L-type Ca2+ channel blocker) restored neurite outgrowth inhibited by GPR143 overexpression to control levels, but had no effect in GPR143-knockdown cells.\",\n      \"method\": \"GPR143 overexpression and knockdown in PC12 cells; pharmacological inhibition with nifedipine, cilnidipine, flunarizine; neurite outgrowth quantification\",\n      \"journal\": \"Journal of pharmacological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection with KD controls, single lab, single method category\",\n      \"pmids\": [\"39068034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"L-DOPA promotes hippocampal neurogenesis through GPR143 in a dopamine-independent manner. L-DOPA at concentrations below those needed for dopamine signaling promoted neural stem/progenitor cell proliferation in wild-type but not Gpr143-/y mice under DOPA decarboxylase inhibition. Gpr143-/y mice show reduced hippocampal neurogenesis and increased depression-like behavior, rescued by re-expression of GPR143 in the dentate gyrus.\",\n      \"method\": \"Gpr143 knockout mice; DOPA decarboxylase inhibition; bromodeoxyuridine proliferation assay; viral re-expression of GPR143 in dentate gyrus; behavioral depression assays\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout + pharmacological decarboxylase inhibition + viral rescue, multiple orthogonal approaches establishing a GPR143-specific and dopamine-independent mechanism\",\n      \"pmids\": [\"35257172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GPR143 oppositely regulates the two isoforms of the dopamine D2 receptor: it potentiates D2L (postsynaptic) function while suppressing D2S (presynaptic autoreceptor) function, as shown by differential effects on quinpirole-induced GSK3β phosphorylation in cells co-expressing each isoform with GPR143.\",\n      \"method\": \"CHO cell co-expression of GPR143 with D2L or D2S; GSK3β phosphorylation assay; dopamine release measurement (in vivo microdialysis); DA neuron-specific Gpr143 knockout (Dat-cre;Gpr143flox/y); haloperidol-induced catalepsy assay\",\n      \"journal\": \"Journal of pharmacological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based signaling assay with isoform specificity plus conditional knockout, single lab\",\n      \"pmids\": [\"39179337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GPR143 (Gpr143) is involved in pulmonary artery vasoconstriction by coupling with adrenergic α1 receptor (ADRA1): L-DOPA pretreatment enhanced phenylephrine-induced vasoconstriction in wild-type but not Gpr143-/y rat pulmonary arteries. Gpr143-/y rats showed attenuated right ventricular systolic pressure in a monocrotaline-induced pulmonary hypertension model.\",\n      \"method\": \"Gpr143 gene-deficient rat generation; isolated pulmonary artery contractility assay; monocrotaline-induced PH model; right ventricular pressure measurement; pulmonary artery smooth muscle cell migration and proliferation assays\",\n      \"journal\": \"Journal of pharmacological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO rat model plus functional vascular assays, single lab\",\n      \"pmids\": [\"35063136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Negative result: L-DOPA-induced ptosis in mice is GPR143-independent, as Gpr143-deficient mice showed ptosis to a similar extent as wild-type mice following L-DOPA administration under DOPA decarboxylase inhibition.\",\n      \"method\": \"Behavioral assay (ptosis scoring) in Gpr143-deficient and wild-type mice with DOPA decarboxylase inhibitor; dose-response analysis\",\n      \"journal\": \"Journal of pharmacological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO with controlled pharmacological treatment, single lab; informative negative result\",\n      \"pmids\": [\"27622543\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GPR143 (OA1) is an intracellular 7-transmembrane GPCR localized to melanosomes and late endosomes/lysosomes via two unconventional sorting signals (a dileucine motif in the third cytosolic loop and a WE doublet in the C-tail); it is ubiquitinated and trafficked through the ESCRT machinery. Its principal endogenous ligand is L-DOPA (with dopamine acting as an antagonist), and upon activation it couples selectively to Gαi3 to regulate melanosome biogenesis—controlling both melanosome number (early stages) and size (stage IV)—and interacts with MART-1 as an escort protein and with melanoregulin linking it to the BLOC pathway. In the central nervous system, GPR143 forms physical complexes with dopamine D2 receptors (via its TM5 domain) and with adrenergic α1 receptors (via TM2) to potentiate their downstream signaling, modulates hippocampal neurogenesis and mood, and inhibits neurite outgrowth via Gα13 and L-type calcium channels. GPR143 also controls ESCRT-dependent exosome biogenesis by interacting with the ESCRT-0 subunit HRS to sort cargo such as EGFR and integrins into intraluminal vesicles.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GPR143 (OA1) is an intracellular seven-transmembrane G-protein-coupled receptor that governs melanosome biogenesis and serves more broadly as an L-DOPA sensor coupling endolysosomal organelle dynamics to G-protein signaling [#0, #3, #13]. It is targeted to lysosomes and melanosomes by two independent, unconventional sorting signals—a dileucine motif in the third cytosolic loop and a WE doublet in the C-tail—both of which must be disrupted to redirect the receptor to the plasma membrane [#2], and it adopts a 7TM topology with its C-terminus facing the cytoplasm [#3]. L-DOPA is its endogenous agonist, triggering calcium influx and beta-arrestin recruitment, with dopamine acting as a competing antagonist [#0]; arrestins in turn downregulate signaling [#1]. Activated GPR143 couples selectively to Gαi3—not Gαi1 or Gαi2—and Gαi3 is the genetic downstream effector, since constitutively active Gαi3 rescues the melanosome phenotype of Oa1-null RPE [#5, #6, #7]. Through this pathway it controls melanosome number at early maturation stages and melanosome size at stage IV, with loss of function producing giant macromelanosomes and optic pathway misrouting [#12, #13], and it acts via an MITF→PMEL transcriptional cascade and partners including the escort protein MART-1 and melanoregulin, which links it to the BLOC-2 pathway [#4, #14, #15]. Mechanistically, GPR143 is ubiquitinated and sorted through the ESCRT machinery into intraluminal vesicles, selectively delaying PMEL-MVB delivery to lysosomes to commit cargo to melanosome biogenesis [#8, #10], and it more generally drives ESCRT-dependent exosome biogenesis by recruiting the ESCRT-0 subunit HRS to cargo such as EGFR, promoting cancer cell motility through integrin/FAK/Src signaling [#9]. In the nervous system and vasculature it functions as an L-DOPA receptor that forms TM-domain-specific heteromers: a TM5 interaction potentiates dopamine D2 receptor signaling (potentiating D2L while suppressing D2S) and a TM2 interaction with adrenergic α1B receptor augments their signaling [#16, #18, #20, #24]. It promotes hippocampal neurogenesis and regulates mood in a dopamine-independent manner [#23], and inhibits neurite outgrowth via Gα13 and L-type calcium channels [#21, #22]. Missense mutations cause ocular albinism either by ER retention/misfolding or by disrupting cytosolic-loop residues required for G-protein coupling [#11].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing the physiological consequence of GPR143 loss showed that the receptor is required for melanosome size control and normal optic pathway wiring, defining the cellular basis of ocular albinism.\",\n      \"evidence\": \"Gene-targeted Oa1 knockout mouse with RPE electron microscopy and retinofugal pathway tracing\",\n      \"pmids\": [\"11092754\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular signaling mechanism producing macromelanosomes\", \"Mechanism of optic fiber misrouting not established\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Systematic mutant analysis resolved how disease alleles fail, separating folding/trafficking defects from signaling defects and implicating the cytosolic loops in effector coupling.\",\n      \"evidence\": \"Expression of 19 missense mutants in COS-7 cells with localization and glycosylation readouts\",\n      \"pmids\": [\"11115845\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G-protein identity not yet known\", \"No structural model of the coupling interface\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defining the receptor's intracellular addressing and constitutive signaling competence showed GPR143 is a bona fide GPCR delivered to lysosomes/melanosomes by two unconventional sorting signals and regulated by arrestins.\",\n      \"evidence\": \"Chimeric LAMP1 fusion constructs and mutagenesis for sorting; COS7 G-protein activation, phosphorylation, and arrestin co-IP\",\n      \"pmids\": [\"16621890\", \"16524428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous ligand not identified\", \"Specific Gα subunit not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Direct topology mapping confirmed GPR143 spans the endolysosomal membrane seven times with a cytoplasmic C-terminus, validating its classification as an intracellular 7TM GPCR.\",\n      \"evidence\": \"HA-tag accessibility with selective permeabilization in COS-1 cells\",\n      \"pmids\": [\"17920058\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address ligand access from the organelle lumen\", \"No high-resolution structure\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identifying L-DOPA as the endogenous agonist and dopamine as antagonist established the receptor's pharmacology and linked activation to calcium, beta-arrestin, and an RPE PEDF autocrine loop.\",\n      \"evidence\": \"Radioligand binding, calcium and beta-arrestin assays, and PEDF secretion in RPE and transfected cells\",\n      \"pmids\": [\"18828673\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a soluble metabolite reaches the intracellular receptor not defined\", \"Did not link ligand binding to melanosome phenotypes in vivo\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Coupling the receptor to a specific G protein, Gαi co-IP and Gαi3-knockout phenocopy placed Gαi3 in the OA1 melanosome pathway.\",\n      \"evidence\": \"Co-IP from melanocytes plus genetic epistasis comparing Gαi3-/- and Oa1-/- mice\",\n      \"pmids\": [\"18378571\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not distinguish among Gαi isoforms\", \"Direct effector mechanism not yet shown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Refining and proving the effector relationship demonstrated Gαi3-selective binding and a reciprocal stability dependence, and ubiquitination/ESCRT studies revealed how the receptor is sorted into intraluminal vesicles.\",\n      \"evidence\": \"GST pull-down and co-IP across Gαi knockouts; ubiquitination assays with ESCRT depletion and EM\",\n      \"pmids\": [\"21931697\", \"21730137\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The ubiquitin ligase acting on GPR143 not identified\", \"Link between Gαi3 signaling and ESCRT sorting not integrated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Genetic rescue with constitutively active Gαi3 in Oa1-null RPE proved Gαi3 is the downstream effector, and parallel work showed OA1 activity selectively delays PMEL-MVB lysosomal delivery.\",\n      \"evidence\": \"Lentiviral Gαi3(Q204L) transgenesis with EM morphometry; OA1 wild-type/mutant expression in PMEL-HeLa cells with MVB and cargo assays\",\n      \"pmids\": [\"24098784\", \"24006264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Gαi3 activity translates into MVB sorting decisions not resolved\", \"Cargo selectivity mechanism not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying protein partners that stabilize and route the receptor and organelle (MART-1, melanoregulin/BLOC-2) and the OA1→MITF→PMEL cascade connected GPR143 to the broader melanosome biogenesis machinery.\",\n      \"evidence\": \"Co-IP and siRNA with EM in melanocytes (MART-1); co-IP and genetic rescue (MREG); loss-of-function/rescue with MITF/PMEL readouts\",\n      \"pmids\": [\"19717472\", \"22984402\", \"24650003\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MITF regulation is direct or downstream of signaling unresolved\", \"Stoichiometry and order of partner assembly not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating GPR143 acts as a functional L-DOPA receptor in defined CNS and vascular contexts extended its role beyond pigmentation to neurogenesis, mood, cardiovascular regulation, and neurite outgrowth.\",\n      \"evidence\": \"In vivo shRNA and antagonism in the NTS; Gpr143 knockout mice/rats with neurogenesis, behavioral, and pulmonary artery assays; PC12 neurite assays with Gα13 knockdown and L-type Ca2+ blockers\",\n      \"pmids\": [\"24117106\", \"35257172\", \"35063136\", \"31606330\", \"39068034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G-protein/effector coupling differs across tissues and is incompletely mapped\", \"Dopamine-independence mechanism in neurogenesis not fully resolved\", \"A negative result shows L-DOPA-induced ptosis is GPR143-independent (PMID 27622543), bounding its pharmacology\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealing TM-domain-specific heteroreceptor complexes showed GPR143 directly modulates other GPCRs—potentiating DRD2 via TM5 and ADRA1B via TM2—and that it drives ESCRT-dependent exosome biogenesis with cancer-relevant cargo via HRS.\",\n      \"evidence\": \"Chimeric domain-swap, co-IP, cAMP/ERK/GSK3β assays, in vivo peptide disruption and conditional knockouts (DRD2/ADRA1B); co-IP, exosome proteomics, and in vivo cancer models (HRS/EGFR)\",\n      \"pmids\": [\"36807226\", \"37394637\", \"38286627\", \"39179337\", \"36800996\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of TM-interface heteromerization not solved\", \"How a melanosomal receptor reaches the plasma membrane to engage cell-surface GPCRs not reconciled\", \"Generality of HRS-cargo sorting beyond EGFR/integrins not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single intracellular L-DOPA receptor integrates G-protein coupling, ESCRT-dependent sorting, and surface heteroreceptor complexes into tissue-specific outputs remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of GPR143 alone or in complex\", \"Mechanism reconciling melanosomal/endolysosomal localization with plasma-membrane heteromer function unknown\", \"Unified model linking Gαi3, Gα13, and arrestin branches across tissues lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [18, 20, 24]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [2, 3, 8]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [8, 10]},\n      {\"term_id\": \"GO:0043226\", \"supporting_discovery_ids\": [12, 13]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [18, 20, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [12, 13, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 18]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [8, 9, 10]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [16, 23, 21]}\n    ],\n    \"complexes\": [\"BLOC-2 (via melanoregulin)\", \"ESCRT-0 (via HRS)\"],\n    \"partners\": [\"GNAI3\", \"MLANA\", \"MREG\", \"HGS\", \"DRD2\", \"ADRA1B\", \"EGFR\", \"GNA13\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}